Literature DB >> 26191304

Myxoid epithelioid gastrointestinal stromal tumor harboring an unreported PDGFRA mutation: report of a case and review of the literature.

Shogo Tajima1, Akihiko Ohata2, Kenji Koda3, Yasuhiko Maruyama2.   

Abstract

Activating mutations of platelet-derived growth factor receptor α (PDGFRA) are detected in a significant proportion of gastrointestinal stromal tumors (GISTs), in addition to the more frequent mutation in c-kit. GISTs with PDGFRA mutations have been found to have several characteristic morphological features, sometimes allowing to discriminate them from GISTs with c-kit mutations. Among these, epithelioid morphology in tumor cells and tumor-infiltrating mast cells are powerful predictors of PDGFRA mutations. Although myxoid stroma by itself is not so much a reliable predictor of PDGFRA mutation, myxoid stroma in conjunction with epithelioid morphology in tumor cells is a powerful predictor of mutations in this gene. GISTs showing either weak or negative immunoreactivity for c-kit and epithelioid cells with myxoid stroma are called myxoid epithelioid GISTs, which typically show PDGFRA mutation. Herein, we presented a case of a 59-year-old woman with myxoid epithelioid GIST of the stomach. A unique finding in this case was eosinophil infiltration, probably more numerous than mast cells; mast cell infiltration is known to be usually found in myxoid epithelioid GIST. The existence of a similar mechanism in eosinophil and mast cell recruitment via tumor-producing stem cell factor is speculated. Mutational analyses revealed a PDGFRA exon 18 mutation: D842_H845del, D846N. Combined deletion and substitution mutation has been reported in rare instances, but to the best of our knowledge, D846N has not been documented.

Entities:  

Keywords:  Myxoid epithelioid gastrointestinal stromal tumor; PDGFRA gene; exon 18; mutation

Mesh:

Substances:

Year:  2015        PMID: 26191304      PMCID: PMC4503175     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors.

Authors:  Florian Haller; Nicole Happel; Hans-Jürgen Schulten; Anja von Heydebreck; Stefanie Schwager; Thomas Armbrust; Claus Langer; Bastian Gunawan; Detlef Doenecke; László Füzesi
Journal:  Mod Pathol       Date:  2007-08-03       Impact factor: 7.842

Review 2.  Gastrointestinal stromal tumors: pathology and prognosis at different sites.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Semin Diagn Pathol       Date:  2006-05       Impact factor: 3.464

3.  Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation.

Authors:  N W Lukacs; R M Strieter; P M Lincoln; E Brownell; D M Pullen; H J Schock; S W Chensue; D D Taub; S L Kunkel
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

4.  Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene.

Authors:  Shinji Sakurai; Tadashi Hasegawa; Yuji Sakuma; Yutaka Takazawa; Atsushi Motegi; Takashi Nakajima; Ken Saito; Masashi Fukayama; Tadakazu Shimoda
Journal:  Hum Pathol       Date:  2004-10       Impact factor: 3.466

5.  DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.

Authors:  Markku Miettinen; Zeng-Feng Wang; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2009-09       Impact factor: 6.394

6.  The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis.

Authors:  A Iemura; M Tsai; A Ando; B K Wershil; S J Galli
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

8.  PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors.

Authors:  Francesca Miselli; Clara Millefanti; Elena Conca; Tiziana Negri; Cristina Piacenza; Marco A Pierotti; Elena Tamborini; Silvana Pilotti
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

9.  Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.

Authors:  Bernadette Liegl; Jason L Hornick; Christopher L Corless; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2009-03       Impact factor: 6.394

Review 10.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Authors:  J Lasota; M Miettinen
Journal:  Histopathology       Date:  2008-02-28       Impact factor: 5.087

View more
  2 in total

Review 1.  Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples.

Authors:  Esther Diana Rossi; Maurizio Martini; Tommaso Bizzarro; Fernando Schmitt; Adhemar Longatto-Filho; Luigi Maria Larocca
Journal:  Oncotarget       Date:  2017-01-10

Review 2.  Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review.

Authors:  Haixin Zhang; Qi Liu
Journal:  Transl Oncol       Date:  2020-06-28       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.